2007 PRESS RELEASES

Tucson, Arizona – December 20, 2007 – CDEX Inc. (OTCBB: CEXI) announces the addition of 43 new signatures to its ValiMed™ Medication Signature Library, bringing the Library’s total to 150 signatures.  (A signature is an electronic fingerprint of a medication at a given concentration in a prescribed diluent.)  “On June 7, 2007, we announced the goal of expanding our Signature Library from 70 to 150 by the end of 2007,” said Malcolm Philips, CDEX CEO.  “Working with our expanding group of Clients, we met that goal, ahead of schedule! And we will continue to expand the Library as directed by the national and international markets.” 

ValiMed™ uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety.  ValiMed compares a medication’s spectroscopic signature to its expected CDEX Library signature and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation. 

“When the CDEX Team develops a ValiMed signature, we test over 400 separate samples of the medication mixture,” said Carlos Alvarez, CDEX’s Manager of Production and Technical Support.  “Then each potential signature is scrubbed though a number of practical and medical gates and sent through a concentration/dilution study before being placed in the CDEX Library for use by our clients.  We know that the accuracy of each signature is important to our clients and the patients that they serve – and it is critical that we get it right.”

For a complete list of the ValiMed Medication Signature Library see www.ValiMed.com or www.CDEX-Inc.com.

Tucson, Arizona – December 18, 2007 – CDEX Inc. (OTCBB: CEXI) demonstrated its ValiMed™ Medical Validation System and Meth Scanner™ to numerous national and international hospital executives, pharmacists, distributors, medical equipment manufacturers and industry representatives at the ASHP trade show in the Sands Expo Center in Las Vegas, Nevada. Pascal Pouligny, CDEX VP of International Sales and Marketing headquartered in Paris, France, demonstrated ValiMed to an enthusiastic international audience. Xavier Guix, Marketing Director at Grifols International stated, “ValiMed has great promise for the international market. By validating the medication itself and not simply the packaging provides a whole new level of patient safety that we are exploring with great interest.” Grifols International, with headquarters in Barcelona, Spain, is a leading, world-wide supplier of medical products and services.

The CDEX Team of Stuart Poteet, Tim Shriver, Jr., Cynthia Sampson, Malcolm Philips, Pascal Pouligny and Tim Shriver, also demonstrated the Meth Scanner to interested representatives including the Governor of Nevada Jim Gibbons and his wife, Dawn Gibbons, and unveiled a new, low-cost Fentanyl Validation System for strengthening procedure to prevent narcotic diversion in medical facilities. In addition, Tim Shriver, CDEX Senior VP of Technical Operations, responded to inquiries from equipment manufacturers about the integrated use of the CDEX technology in medical equipment that distributes controlled substances and equipment that automatically compounds medications. “The continued expansion of the ValiMed Signature Library offers us the opportunity to consider integration of our technology into related medical products,” said Mr. Shriver. “This is an exciting expansion that we looked at three years ago and are now ready to explore aggressively.” View photos

ValiMed™ uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to its expected CDEX Library signature and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation. ValiMed is currently saving lives in hospitals across the nation.

Tucson, Arizona – December 17, 2007 - CDEX Inc. (OTCBB: CEXI) recently demonstrated its new ID2, Methamphetamine Scanner (“Meth Scanner”) to Nevada Governor Jim Gibbons and First Lady Dawn Gibbons, who continue to lead efforts to combat methamphetamine production and use.  Malcolm Philips, CEO of CDEX, explained the technology behind the Scanner and that it had been involved in several busts during its beta testing.  “This technology could certainly provide much needed assistance for our law enforcement’s efforts to crack down on the production, transportation, and use of methamphetamine,” said Governor Jim Gibbons.

Visiting the ASHP trade show at the Sands Expo Center in Las Vegas, Mrs. Gibbons stopped by the CDEX booth to learn more about the technology and progress on deploying the Meth Scanner in the field.  .”  Mrs. Gibbons used the Scanner to identify trace quantities of methamphetamine on baby clothes.  “The children are the hidden victims of methamphetamine use,” said Mrs. Gibbons.  “We are beginning to understand the devastating impact of meth on users and those exposed to high levels.  We do not fully understand the long term impacts of extended low level exposure such as from living in a house or apartment where meth had been made or used. That may be a ticking time bomb, particularly for children.”   (For additional photographs of Mrs. Gibbons’ visit see http://firstlady.state.nv.us/DawnGibbons_OutAbout.htm.)

The Meth Scanner identifies trace quantities of methamphetamine on all surfaces while in a continuous scan mode. The Scanner, weighing less than 1½ pounds, is battery operated, handheld, non-intrusive and requires no operator interpretation of results.  As to the schedule for deployment of the scanner, Philips stated, “we have received great cooperation from law enforcement agencies in Nevada, Texas, Missouri and Arizona in refining the Meth Scanner.  We will put it on the market as soon as we finish the sensitivity testing in the next several weeks and it will be ready for delivery during the first quarter of the 2008.”

The CDEX Methamphetamine Scanner uses the same basic technology employed in the CDEX ValiMed™ Medication Validation System, demonstrated at the ASHP trade show.  ValiMed uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety.  ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation. ValiMed is currently saving lives in hospitals across the nation.

Tucson, Arizona – December 2, 2007 – CDEX Inc. (OTCBB: CEXI) announces that effective November 27, 2007, it has taken steps to strengthen its Corporate structure by amending its Bylaws and realigning its Board of Director Committees. “With the growing number of ValiMed™ hospital clients and commercialization of our Methamphetamine Scanner, we are receiving increasing national and international visibility and inquiries regarding our company,” said Malcolm Philips, CEO and Chairman of the Board of CDEX Inc. “In the face of this increasing exposure, the Board instituted Bylaw changes to strengthen the corporate structure. In addition, taking advantage of the expanding expertise on our Board, we have restructured Committee assignments and adopted new Committee Charters for our Audit, Compensation and Corporate Governance Committees. These steps will result in a more structured Board oversight of CDEX company actions, providing greater protection for our shareholders.” The amendments to the Bylaw are detailed in the required SEC 8K filed on December 2, 2007.

The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

The Methamphetamine Scanner uses the same basic technology employed in ValiMed to identify trace quantities of methamphetamine on all surfaces while in a continuous scan mode. The Scanner, weighing less than 1½ pounds, is battery operated, handheld, non intrusive and requires no operator interpretation of results. The Scanner is undergoing final testing and is expected to be available for delivery in the first quarter of 2008.

Mr. Pascal Pouligny joins CDEX Inc. as Vice President of International Sales and Marketing to launch ValiMed™ into the International Health Care and Hospital Markets.

Tucson, Arizona and Paris, France – November 5, 2007 – CDEX Inc. (OTCBB: CEXI) follows up on its record quarter in ValiMed™ sales/leases to U.S. hospitals by announcing that Mr. Pascal Pouligny has joined CDEX as Vice President of International Sales and Marketing to launch ValiMed into the International health care and hospital markets. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety.  ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

Mr. Pouligny has served in senior management positions in a number of companies over the past 20 years, with a primary focus on international sales and marketing to the healthcare market. He has successfully launched new medical products and services into the European, Middle East, and Asian markets for startup and major companies. (Mr. Pouligny’s bio is on the CDEX web site at HYPERLINK "http://www.cdex-inc.com" www.cdex-inc.com.)

“ValiMed presents an innovative and proven technology that is needed in the world healthcare markets,” said Mr. Pouligny. “I look forward to working with the CDEX Team as we launch this product into the international marketplace.”

“Pascal is a well respected and seasoned executive who has successfully launched many medical products and services throughout the world” said Malcolm Philips, CDEX CEO. “We look forward to his leadership in establishing reference testing partners, developing channel sales networks and implementing the sales/marketing strategy first for Europe and then beyond.”

CDEX CEO Malcolm Philips will appear on Market News 1 at 10:00 AM (CT) on Tuesday, October 23, 2007.

Tucson, Arizona – October 19, 2007 – CDEX Inc. (OTCBB: CEXI) announces a record quarter in ValiMed™ sales/leases to hospitals.  (A listing of hospitals with contracts for the sale/lease of one or more ValiMed™ units is contained on the CDEX WebSite at www.cdex-inc.com.) The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety.  ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

“Our clients are some of the best and most progressive hospitals in the country today,” said Malcolm Philips, CDEX CEO.  “We are honored that they have selected the CDEX ValiMed System.  We are also very pleased that our growing list of clients reflects a combination of first time purchases/leases and second unit purchases by existing clients.  The ValiMed Product Line (currently saving lives in hospitals today) when coupled with our Methamphetamine Scanner (market entry planned for 2007) puts our patented technologies squarely in two different markets, with more to come.”     

Tucson, Arizona – October 9, 2007 – CDEX Inc. (OTCBB: CEXI) announces that Carmen J. Conicelli replaces Dr. BD Liaw, Chairman of the Board, on the CDEX Board of Directors. Dr. Liaw, who resigned from the Board for health reasons, will continue to support CDEX particularly in relation to establishing international markets for CDEX products. Malcolm H. Philips, President and CEO, will assume the additional responsibilities of Chairman.

“It is with deep personal regret that the Company accepts Dr. Liaw’s resignation,” said Mr. Philips. “Dr. Liaw has had a long and distinguished career of service to this country in senior executive positions with the U.S. Nuclear Regulatory Commission, to Taiwan Power Company as an Executive Director and senior consultant, and to CDEX as a founding Director and later as Chairman of the Board. I know that he will continue to provide strong and effective support for CDEX as we move into the international market.”

Mr. Conicelli is the CFO of Edmund Optics, Inc. and has had a distinguished career in finance and management. . “CDEX is pleased to have Mr. Conicelli join us as a Board member,” said Malcolm Philips. “He brings to the Board more than 30 years of experience in finance and accounting with a strong background in international finance and business. Mr. Conicelli will be invaluable to CDEX as we broaden our domestic markets and enter the international medical and security markets.”

CDEX CEO, Malcolm Philips, will appear on WallSt.net (http://www.wallst.net) at 1:00PM (PST) on Tuesday, September 25, 2007. 

Tucson, Arizona – September 24, 2007 – CDEX Inc. (OTCBB: CEXI) announces the addition of 19 new signatures to its ValiMed™ Medication Signature Library, bringing the Library’s total to 107 signatures. (A signature is an electronic fingerprint of a medication at a given concentration in a prescribed diluent.) Signature development for the ValiMed System is ahead of schedule to meet the goal of 150 signatures by the end of 2007. The ValiMed System, developed by CDEX, provides hospital clinicians with a quick, cost effective and simple tool to assure medication safety by verifying that medications are compounded correctly and to minimize the risk of narcotic diversion by validating the narcotic medications returned to the pharmacy for disposal.

Using Enhanced Photoemission Spectroscopy, ValiMed quickly validates high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

“When the CDEX Team develops a ValiMed signature, we test over 400 separate samples of the medication mixture,” said Carlos Alvarez, CDEX’s Manager of Production and Technical Support. “Then each potential signature is scrubbed though a number of practical and medical gates and sent through a concentration/dilution study before being placed in the CDEX Library for use by our clients. We know that the accuracy of each signature is important to our clients and the patients that they serve – and it is critical that we get it right.”

“We are working with our growing client base to prioritize the development of signatures based on their needs,” said Stuart Poteet, Manager of Marketing and Client Support. “It is important for us to meet the goal of 150 signatures by the end of the year and we fully expect to do so.”

For a complete list of the ValiMed Medication Signature Library see www.valimed.com or www.cdex-inc.com

CDEX CEO, Malcolm Philips, will appear on MN-1 at 1:00PM (CT) on Thursday September 20, 2007.

Tucson, Arizona – September 20, 2007 – CDEX Inc. (OTCBB: CEXI) announces the results of testing by the Greenlee County Sheriff’s Department of the CDEX ID2 (“Meth Scanner™”).  The Greenlee County Sheriff’s Department tested the ability of the Meth Scanner to detect trace quantities of methamphetamine on various surfaces including clothing, baby toys and hard surfaces.  Portions of the target surfaces were contaminated with trace quantities (less than the eye can see) of methamphetamine supplied by the Sheriff’s Department.  Contaminated and uncontaminated surfaces were scanned by members of the Sheriff’s Department and the results tabulated. The Meth Scanner detected the trace quantities of methamphetamine 100% of the time with no false positives. (The report is contained on the CDEX web site at www.cdex-inc.com.)

The CDEX ID2 (‘Meth Scanner”) is a hand held, battery operated device that detects trace quantities of methamphetamine on surfaces, including clothing and skin, in a continuous scan mode  from standoff distances of 2-8 inches.  The Meth Scanner requires no operator interpretation of results and detects methamphetamine in a continuous scan mode without damaging the substance under investigation. The Meth Scanner is in its second round of beta testing with Law Enforcement Agencies.

“The Greenlee County Sheriff’s Department has been an outstanding beta partner testing the Meth Scanner in the field and the lab,” said Tim Shriver, Jr., CDEX Project Manager for the Meth Scanner.  “They have given us good feedback on use of the ID2 resulting in improvements in a number of areas.  We are talking with potential distribution partners for the Meth Scanner and expect to begin marketing in CY 2007.”

ValiMed™ 3rd Quarter Revenues and 4th Quarter Sales Contracts Increase

Tucson, Arizona – September 14, 2007 – CDEX Inc. (OTCBB:CEXI) Today, CDEX filed its 3rd Quarter Form 10QSB for FY 2007 reporting, among other things, (1) an increase in revenues over corresponding 2006 revenue figures (e.g., 36% increase in reported revenues for the first 9 months of FY 2007 vs. the first 9 months of FY 2006) and (2) an increase in contracts for the sale or lease of ValiMed™ Units to new and existing hospital clients. In addition, on August 17, 2007, CDEX filed a Form 8K that contains a CDEX information presentation.

Using Enhanced Photoemission Spectroscopy, a CDEX ValiMed™ Unit quickly validates high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed™ compares a medication’s spectroscopic signature to the Unit’s medication signature library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation. CDEX is continuing to build the CDEX Medication Signature Library, which currently contains over 88 unique pharmaceutical signatures and is expected to grow to over 150 by the end of 2007.

“We project that during the 4th Quarter of FY 07, CDEX will execute more contracts for the sale or lease of ValiMed™ Units to hospitals than in any quarter to date,” stated Malcolm Philips, CEO of CDEX. “As the number of ValiMed™ Units in the field grows, our recurring revenue stream will also continue to grow. The increase in the number of contracts with new and existing clients validates the product expansion efforts that the CDEX Team went through earlier this year.”

Tucson, Arizona – August 10, 2007 – Malcolm Philips, Chief Executive Officer of CDEX, Inc. (OTCBB: CEXI) (www.cdex-inc.com) updated the investment community in an all-new interview with www.wallst.net. Topics covered in the interview include an overview of the company and its growth strategy, recent press releases, market opportunity, and upcoming milestones for investors to watch for.

To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window.

About WallSt.net

www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com), a provider of media and compliance solutions to publicly traded companies. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com), a business and finance podcast Web site. Financial Filings Corp. is expecting to receive two hundred eighty dollars from CDEX, Inc. for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.

Contact:           www.WallSt.net

                        800-4-WALLST

CDEX’s ValiMed™ Medication Library reaches 88 signatures with development ahead of the 150 signature goal by the end of 2007.

Tucson, Arizona – July 26, 2007 – CDEX Inc. (OTCBB: CEXI) announces the addition of 16 new signatures to its ValiMed™ Medication Signature Library. The ValiMed System, developed by CDEX and distributed by Baxa Corporation, provides hospital clinicians with a quick, cost effective, and simple tool to further ensure medication safety by verifying that medications are correctly compounded.

Using Enhanced Photoemission Spectroscopy, ValiMed quickly validates high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

“We are working with our new and existing customers to prioritize the compounded medications that they need as we schedule new signature development,” said Carlos Alverez, CDEX’s Manager of Production and Technical Support. “When our team develops a ValiMed signature, we test over 400 separate samples of the medication and by computer do over one million individual mathematical comparisons. Then the potential signature is scrubbed though a number of practical and medical gates before it is placed in the CDEX Library for use by our clients. We know that the accuracy of each signature is important to our clients and the patients that they serve – and it is critical that we get it right.”

“The addition of these 16 signatures brings our ValiMed Signature Library to 88 signatures and puts us ahead of schedule to meet our commitment of having an available library of 150 medication signatures for our customer’s use by the end of the year,” said Stuart Poteet, Manager of Marketing and Client Support. Being able to surpass the established schedule for the development of the medication signatures, while we continue to schedule the backlog for the installation of ValiMed systems purchased by both new and repeat customers, reaffirms our commitment to our customers and to improving patient safety.”

For a complete list of the ValiMed Medication Signature Library see www.valimed.com.

About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Key Automated Syringe Fillers, Exacta-Med products include Rapid-Fill™ ® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, and Exacta-Mix™ and MicroMacro™ Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg and The Netherlands; and distribution partners worldwide. Further information is available at www.baxa.com.

CDEX implements second round of beta testing and implements new features for law enforcement

Tucson, Arizona – July 24, 2007 – CDEX Inc. (OTCBB: CEXI) announces that it has increased sensitivity and added scan capability to its hand held methamphetamine detection device (ID2) in preparation for a second round of beta testing scheduled to begin at multiple locations in August 2007. In response to market testing, improvements made to the ID2 include a continuous scan capability, increased sensitivity, a greater scan area, a targeting device and a range indictor to assist the operator in detector positioning. The increased sensitivity allows the identification of trace quantities of methamphetamine on most surfaces including skin and clothing.

“In cooperation with our law enforcement partners, CDEX has been able to make significant improvements in both the technical capabilities and the operator usability of the Meth Gun,” said Tim Shriver, Senior VP of Technical Operations at CDEX. “We have the final design on the drawing board and have begun discussions with our vendors and manufacturer anticipating starting commercial production by the end of the year.”

“In response to numerous national and international inquiries, with the help of our marketing consultants, we are exploring markets for the ID2 beyond the traditional law enforcement community, including correctional facilities, rehabilitation facilities, school systems and general public applications,” said Stuart Poteet, CDEX’s Manager of Marketing and Client Support.

Baxa Corporation is promoting its industry-leading STAR Center pharmacy training facility, CriticalPointTM online sterile compounding certification training, Abacus TPN ordering and calculation software and the ValiMed System for medication validation at the American Society of Health-System Pharmacists 2007 Summer Meeting and Exhibition beginning today at the Moscone Center in San Francisco.

Englewood, CO – June 25, 2007 – At the annual ASHP Summer Meeting and Exhibition, Baxa Corporation is promoting the benefits of specialty pharmacy software, USP <797> compliance training and medication validation equipment for improving pharmacy operations and reducing the opportunity for medication errors. During the three-da exhibition, Baxa will demonstrate the capabilities of the latest release of its Abacu TPN order entry and calculation software. The Baxa sales team also will discuss the pharmacy training programs available at its Skills Training, Academics and Resources (STAR) Center. Among the equipment available in the booth for demonstration during the show is the ValiMed Medication Validation System, distributed by Baxa Corporation.

The San Francisco meeting serves as the launch for a new online training program that Baxa is marketing – CriticalPoint. This step-by-step, online training consists of 32 individual modules that build a foundation of best practice for pharmacists and technicians involved in sterile compounding. The CriticalPoint curricula were developed by industry experts as a cost-effective means to comply with the aseptic training requirements for USP <797>. The modules complement the hands-on training offered through the Baxa STAR Center

Also featured at the ASHP meeting is the ValiMed Medication Validation System. ValiMed uses enhanced photoemission spectroscopy to validate high-risk medication admixtures and returned narcotics to provide an increased level of patient safety. Manufactured by CDEX Inc., the system compares a medication’s spectroscopic signature to the unit’s Medication Signature Library, returning an easy-to-understand audible and visual ‘validated’ or ‘not validated’ result. ValiMed is the only system that provides real-time validation of medication and concentration, giving pharmacists a tool for med error prevention, as well as auditing narcotic returns. Reports generated from validation results facilitate compliance with USP <797> quality, Inc.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery.  Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications.  Key Automated Syringe Fillers, Exacta-Med products include Rapid-Fill™ ® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, and Exacta-Mix™ and MicroMacro™ Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities.  Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg and The Netherlands; and distribution partners worldwide.  Further information is available at www.baxa.com.

About CriticalPoint, LLC
CriticalPoint, LLC, offers interactive Web-based training for compounding sterile
preparations and services related to creating and enabling learning through technology in clinical settings. CriticalPoint e-Learning represents a best practices approach for interactive training for sterile compounding and is designed to assist healthcare providers in meeting quality assurance program goals and regulatory compliance. For more information visit www.criticalpoint.info.

About the STAR Center
The STAR Center is a state-of-the-art cleanroom, pharmacy and training facility located at the Baxa world headquarters in Englewood, Colorado. The center was purpose-built to support training in aseptic technique, pharmacy workflow and practice, cleanroom design and maintenance and USP <797> compliance among other topics. Classes are taught by industry-recognized subject matter experts.
Further information is available at www.baxa.com.

Contacts:
Baxa Corporation
Marian Robinson, Vice President, Marketing
800.567.2292 ext. 2157 or 303.617.2157
Email:  marian.robinson@baxa.com

Maggie Chamberlin Holben, APR, Absolutely Public Relations
303.984.9801, 303.669.3558 Email: maggie@absolutelypr.com
http://www.absolutelypr.com

CDEX Inc.
Malcolm Philips or Stuart Poteet
520.745.5172
mphilips@cdex-inc.com
spoteet@cdex-inc.com

The ValiMed Medication Validation System and related information are now available at PublicRelationsNewsroom.com The ValiMed System, distributed by Baxa Corporation, offers clinicians a simple and cost-effective tool to ensure medication safety by verifying that medications are correctly compounded. Its patented technology validates compounded doses of high risk medications prior to dispensing.

Englewood, CO, June 15, 2007 – The ValiMed Medication Validation System and related information are now available at http://publicrelationsnewsroom.com/_wsn/page19.html for media and professional access. ValiMed, distributed by Baxa Corporation, uses enhanced photoemission spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the Medication Signature Library and returns an easy-to-understand “validated” or “not validated” result, requiring no user interpretation.

The expanded ValiMed System features patented technology that validates in seconds compounded doses of high-risk medications prior to dispensing. Verification of compounding accuracy is a requirement under USP 27-NF 22 Chapter <797>, which regulates the compounding of sterile products. The ValiMed System can play a key role in demonstrating the safety of compounded sterile products (CSPs) under these requirements.

This expanded ValiMed System incorporates reports supporting compliance with USP 797 requirements. It also features a modified disposable, requiring a reduced (0.25 mL) sample volume for testing. “This next- generation ValiMed System addresses customer requests,” notes Baxa Corporation Product Manager Mark Thrasher. “The addition of a quality assurance feature meets the regulatory requirements, while the smaller sample requirement more easily accommodates current pharmacy work flows.”

Baxa, a long-time proponent of hospital pharmacy safety initiatives recently launched its state-of-the-art STAR (Skills Training, Academics and Resources) Center for pharmacy and cleanroom skills training. Products such as the ValiMed Medication Validation System can be demonstrated and evaluated there, as part of a technology overview for best practices. Baxa designed and built the STAR Center as a fully USP 797-compliant pharmacy cleanroom to provide professional education on pharmacy practice, cleanroom principles and compliance to regulatory requirements. The STAR Center, the only dedicated facility of its kind in the world for hands-on cleanroom experience and training in environmental monitoring and aseptic technique, provides a unique opportunity for industry professionals to learn best practice from subject-matter expert trainers. More information is available at http://www.baxa.com/starcenter.

Founding CEO returns to lead Company’s expansion in Health and Security Markets

Tucson, Arizona – June 11, 2007 – CDEX Inc. (OTCBB: CEXI), the developer of innovative systems for substance detection and verification, announced today that Malcolm Philips has been named President and Chief Executive Officer. Mr. Philips was the President, CEO and Chairman of the Board of CDEX from its inception until he left the Company in early 2006. Since December 2006, Mr. Philips has been a special advisor to the Board and Mr. Tim Shriver, who has been serving as acting President and CEO, to consolidate operations in Tucson, Arizona . With completion of the transition and consolidation, the senior management team of Mr. Philips as CEO and Mr. Shriver as Senior Vice President of Technical Operations will continue to lead the company.

“In the last four months, the CDEX Team has not only consolidated offices in Tucson, but also expanded the ValiMed™ Medical Validation System product line and Medication Signature Library, upgraded the Methamphetamine Detection Unit for a second round of beta testing and prepared the ValiMed™ LVM (a mobile, battery operated fentanyl detector) for beta testing,” said Mr. Philips. “With the announcement of the launch of our expanded ValiMed™ product line yesterday, and having additional products close to launch, we feel very well positioned for the future.”

CDEX Inc. (www.cdex-inc.com) is the developer of the ValiMed™ Medication Validation System. Using Enhanced Photoemission Spectroscopy, ValiMed™ quickly validates high-risk medication admixtures, as well as returned narcotics to provide an increased level of patient safety. ValiMed™ compares a medication’s spectroscopic signature to the Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation. In conjunction with priority requests from existing and future clients, CDEX is continuing to build its signature library, which currently contains over 70 unique pharmaceutical signatures and is expected to grow to over 150 by the end of 2007.

“The vision and growth strategy of Mr. Philips and Mr. Shriver is fully supported by the CDEX Board of Directors,” said Dr. B.D. Liaw, Chairman of the Board. “We have been pleased with the speed and results of the Tucson consolidation and look forward to their leadership for the future.”

Tucson, Arizona – June 7, 2007 – (OTCBB: CEXI) announces the expansion of its ValiMed™ Product Line to allow greater cost accessibility for the full spectrum of medical care facilities. The ValiMed™ expansion includes more robust and sensitive medication signature recognition software and an expanded Medication Signature Library.

“With the enhanced Valimed™ unit and the addition of a QA audit capability for monitoring pharmacy compounding practices,” said Pam Price, Senior Vice President of Sales and Service for Baxa Corporation, the exclusive distributor of the ValiMed™ System; “our sales force is excited about and aggressively introducing ValiMed™ technology to our customers.”

Using Enhanced Photoemission Spectroscopy, ValiMed™ quickly validates high-risk medication admixtures, as well as returned narcotics to provide an increased level of patient safety. ValiMed™ compares a medication’s spectroscopic signature to the Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation. CDEX is continuing to build its signature library, which currently contains over 70 unique pharmaceutical signatures and is expected to grow to over 150 by the end of 2007.

“Our expanded ValiMed™ solution provides greater functionality and detection sensitivity that we believe brings true value to our clients and a higher level of safety to patients at healthcare facilities,” said Malcolm Philips, Founding CEO and Chairman of the Board. “This expanded product line allows CDEX to provide a ValiMed™ Unit that addresses medication validation needs of most medical care facilities, not just the mega hospitals. Today, we have a backlog of clients that are awaiting installation of expanded ValiMed™ units and we are preparing to start that delivery process.”

About CDEX, Inc.

CDEX, a technology development company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the Meth Scanner™ are CDEX solutions for the healthcare and security markets.  Corporate headquarters and R&D facilities are located in Tucson, Arizona.  For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) at 520.745.5172 X210.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery.  Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications.  Key Automated Syringe Fillers, Exacta-Med products include Rapid-Fill™ ® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, and Exacta-Mix™ and MicroMacro™ Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities.  Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg and The Netherlands; and distribution partners worldwide.  Further information is available at www.baxa.com.

Contacts:
For Baxa Corporation
Marian Robinson, Vice President, Marketing
800.567.2292 ext. 2157 or 303.617.2157
Email:  marian.robinson@baxa.com

For CDEX Inc.
Malcolm Philips or Stuart Poteet
520.745.5172
Email:  mphilips@cdex-inc.com or spoteet@cdex-inc.com

Tucson, Arizona – (Market Wire) – May 16, 2007 –CDEX's (OTC BB:CEXI.OB - News) founding CEO and Chairman, Malcolm Philips, will be interviewed by MN1 on May 17, 2007, at 12:30 PM EDT to discuss the general structure of CDEX and it's technology, the Beta Cycle trials of CDEX's Methamphetamine Detection Unit, the Company's Medical product line -- ValiMed(TM) and CDEX's ongoing research programs. "We believe that our company is poised for growth in the marketplace and we are starting the process of introducing potential investors to this opportunity," said Mr. Philips.

About MN1.com

Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

ValiMed Makes Market Debut and Company Signs New Investment

Tucson, Arizona – February 5, 2007 –CDEX Inc. (OTCBB:CEXI) Today, CDEX filed its 10K for fiscal year 2006 reporting, among other things, first shipments of its ValiMed product line through Baxa Corporation, its exclusive distributor in the U.S. and Canada. Sales of Valimed units have resulted in the highest annual revenue in the Company’s history and gross margins continued in excess of 50%.

“Fiscal year 2006 saw the introduction of our first production units of ValiMed into the medical markets, and we expect to ship our first Methamphetamine Detection products into the security markets in 2007” said Tim Shriver, President and CEO. “As the Company has moved from technology development to product implementation, we have looked for opportunities to streamline our operations in product development, sales and marketing, and administrative expenses, and have done so. Significantly, the company closed over $225k of new funding in January, and signed agreements for additional funding to begin in the second quarter of FY 2007.”

The Company has scheduled a 45 minute conference call for interested persons for Friday February 9 at 10:00 AM EST to discuss the SEC filings. The call will be limited to the first 50 individuals to call in. A recording of the call will be posted on the Company’s web site for the following three weeks for those interested.

Conference Call Details: The moderator will begin accepting calls from participants 10 minutes prior to the start of the call. You will need to identify yourself and state if you are an investor or a member of the general public before being connecting into the conference call.

Dial-In:

Local / International: 416-640-3404
North American Toll- Free: 1-866-322-1159

Conference ID: CDEX 10K Conference Call

Links to SEC documents:

10-K http://www.sec.gov/Archives/edgar/data/1173738/000121465907000218/0001214659-07-000218.txt

10-Q restatements http://www.sec.gov/Archives/edgar/data/1173738/000121465907000214/0001214659-07-000214.txt

10-Q restatement http://www.sec.gov/Archives/edgar/data/1173738/000121465907000213/0001214659-07-000213.txt

8-K http://www.sec.gov/Archives/edgar/data/1173738/000121465907000211/0001214659-07-000211.txt